Commenting on the study: efficacy and safety of maintenance treatment with pemetrexed in patients with advanced NSCLC nonskvamózním after induction therapy with pemetrexed plus cisplatin - comparison studies JMBD and PARAMOUNT
Abstract
Pemetrexed in combination with cisplatin is indicated as first-line treatment of patients with advanced NSCLC nonskvamózním (NSCLC) - JMDB in the study were in this subgroup of patients during treatment with pemetrexed + cisplatin recorded longer survival than those treated with gemcitabine plus cisplatin. The study demonstrated the efficacy PARAMOUNT then follow pemetrexed in patients who were after four cycles of induction therapy with pemetrexed + cisplatin achieved an objective response or stable disease.
In clinical practice, and in many guidelines using induction therapy (if achieved response) recommended six cycles of pemetrexed + cisplatin. The question thus arises whether six cycles of induction therapy does not produce the same results as four cycles followed by maintenance therapy with pemetrexed.